drugset / Trial / NCT01810783

Brexpiprazole in Patients With Schizophrenia

NCT01810783

NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of brexpiprazole during long-term treatment.

Timeline

Start
2013-07
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 1 mg Oral
Subject Brexpiprazole Small molecule 2 mg Oral
Subject Brexpiprazole Small molecule 3 mg Oral
Subject Brexpiprazole Small molecule 4 mg Oral

Indications